Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oral-Pro Pyrantel Pamoate Oral Suspension
- Development stage
- Unknown
- Lead developer
- Aurora Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Oral-Pro is an approved anthelmintic medication developed by Aurora Pharmaceutical for the treatment of human parasitic helminth infections, specifically pinworms (Enterobius vermicularis). The active ingredient is pyrantel pamoate, a small molecule that acts as a depolarizing neuromuscular blocking agent. It works by inducing spastic paralysis in the parasitic worms through the activation of nicotinic acetylcholine receptors on their muscle cells. This immobilization prevents the worms from maintaining their grip on the intestinal wall, allowing the host's body to naturally eliminate them through defecation. The medication is formulated as a vanilla custard-flavored oral suspension containing 50 mg/mL of pyrantel base and is indicated for use in adults and children aged 2 years and older.
- Brand names
- Oral-Pro
- Other names
- pyrantel pamoateOral-Pro Pyrantel Pamoate
02
Targets
Nicotinic Acetylcholine Receptor
Beyond the preview
Go deeper on Oral-Pro Pyrantel Pamoate Oral Suspension.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oral-Pro Pyrantel Pamoate Oral Suspension.